Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
New Haven, CT
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
New Haven, CT
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Investigative Site
mi
from
Fort Myers, FL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Investigative Site
mi
from
Fort Myers, FL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Hollywood, FL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Hollywood, FL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Athens, GA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Athens, GA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Investigative Site
mi
from
Lawrenceville, GA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Investigative Site
mi
from
Lawrenceville, GA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Niles, IL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Niles, IL
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Indianapolis, IN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Indianapolis, IN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Baltimore, MD
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Baltimore, MD
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Lansing, MI
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Lansing, MI
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Jackson, MS
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Jackson, MS
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Lincoln, NE
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Lincoln, NE
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Henderson, NV
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Henderson, NV
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Albuquerque, NM
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Albuquerque, NM
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Charlotte, NC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Charlotte, NC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Fargo, ND
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Fargo, ND
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Cincinnati, OH
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Cincinnati, OH
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Oklahoma City, OK
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Oklahoma City, OK
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Columbia, SC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Columbia, SC
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Kingsport, TN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Kingsport, TN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Tennessee Oncology
mi
from
Nashville, TN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Oncology
mi
from
Nashville, TN
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Bedford, TX
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Bedford, TX
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Roanoke, VA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Roanoke, VA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Burien, WA
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Keryx / AOI Pharmaceuticals Investigative Site
mi
from
Burien, WA
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
UH-Richmond
mi
from
Richmond Heights, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
UH-Richmond
mi
from
Richmond Heights, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Lake Shore Pediatrics
mi
from
Libertyville, IL
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
Lake Shore Pediatrics
mi
from
Libertyville, IL
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Drug-Drug Interaction Study of the Effects of XL184 on Rosiglitazone in Subjects With Solid Tumors
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY 94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation.
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY 94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Bettendorf, IA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bettendorf, IA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ